Cevostamab not checked

Roche · RO7187797

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
10 active
11 in total · 8 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants will receive cevostamab IV as per the schedule given in the protocol.”In the company’s words, NCT07555938 on ClinicalTrials.gov
Tested for
Multiple Myeloma (7 trials), Relapsed or Refractory Multiple Myeloma, Lupus Erythematosus, Systemic, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Main trialPhase 3
“The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.”In the company’s words, NCT07555938 on ClinicalTrials.gov
Other names
RO7187797

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up10

Changes1

Last 90 days

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Nov 2028 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Phase 2Recruiting 13 Apr 2029 Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Phase 1/2Active, not recruiting 26 Feb 2027 A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2Recruiting 31 Jul 2028 A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1Active, not recruiting 18 Nov 2026 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1Recruiting 31 Jul 2027 A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1Active, not recruiting 15 Nov 2028 A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Phase 1Recruiting 21 Dec 2028 A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1Recruiting 29 Mar 2030 To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Phase 1Active, not recruiting 17 Jun 2030 A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1Completed 7 Jan 2026 Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cevostamab

Following is part of Solo: you see every change to Cevostamab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in